Nevertheless, one could say that the follow-up of patients with liver metastases is individualized on the basis of their clinical status (including symptoms) and degree of tumor differentiation, making use of a combination of laboratory tests and tumor markers (including chromogranin A), as well as (anatomical and functional) imaging findings(9). The gene discussed is CHGA; the disease is neoplasm.